bioRxivCancer BiologyPreprint
Immune-evasion of KRAS-mutant lung adenocarcinoma mediated by cAMP response element-binding protein
G. A. Giotopoulou, G. Ntaliarda, A. Marazioti, I. Lilis, F. Kalogianni, E. Tourkochristou, N. Spiropoulou, I. Giopanou, M. Spella, M. Iliopoulou, A. Korfiati, T. Mantamadiotis, C. Rosero, T. Goldmann, S. Marwitz, G. T. Stathopoulos
Abstract
cAMP response element-binding protein (CREB) mediates proliferative and inflammatory gene transcription in neurodegeneration and cancer, but its role in malignant immune-evasion of lung adenocarcinoma (LUAD) is unknown. We show that human LUAD of smokers are frequently altered along the CREB pathway and we employ mouse models to discover that KRAS-mutant LUAD co- opt CREB to evade immune rejection by tumoricidal neutrophils. For this, KRAS- driven CREB activation suppresses CXC-chemokine expression and prevents recruitment of CXCR1+ neutrophils. CREB1 is shown to be pro-tumorigenic in five different LUAD models, a function that is dependent on host CXCR1. Pharmacologic CREB blockade prevents tumor growth and restores neutrophil recruitment only when initiated before immune-evasion of KRAS-mutant LUAD. CREB and CXCR1 expression in human LUAD are compartmentalized to tumor and stromal cells, respectively, while CREB-regulated genes and neutrophils impact survival. In summary, CREB-mediated immune evasion of KRAS-mutant LUAD relies on signaling to neutrophil CXCR1 and is actionable.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell-cell communication
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma
S. Laing, B. Kruspig, … D. J. Murphy·bioRxiv·Jul 24, 2023
- Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma
Sophie de Carné Trécesson, Philip East, … Julian Downward·bioRxiv·Nov 25, 2025
- Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer
Siddharth Mehra, Supriya Srinivasan, … Nagaraj S. Nagathihalli·bioRxiv·Dec 8, 2025
- An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations
J. Boumelha, S. de Carne Trecesson, … J. Downward·bioRxiv·Dec 22, 2020
- Mutant KRAS promotes NF-kB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma
Donovan Drouillard, Marissa Davies, … Michael B. Dwinell·bioRxiv·Apr 15, 2026
- CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer
J. Boumelha, A. de Castro, … J. Downward·bioRxiv·Apr 13, 2023